Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17395780 | 1.00 | LMNA (0.45) | LMNASMN1; SMN2MAPK1ALDH1A1MAPT | |
| SCHEMBL17402468 | 0.90 | LMNA (0.49) | LMNASMN1; SMN2MAPK1ALDH1A1MAPT | |
| SCHEMBL18437980 | 0.90 | LMNA (0.49) | LMNASMN1; SMN2MAPK1ALDH1A1MAPT | |
| SCHEMBL18888891 | 0.89 | ALDH1A1 (0.48) | LMNASMN1; SMN2MAPK1ALDH1A1MAPT | |
| SCHEMBL18474179 | 0.89 | ALDH1A1 (0.48) | LMNASMN1; SMN2MAPK1ALDH1A1MAPT | |
| SCHEMBL18915418 | 0.88 | NPC1 (0.45) | LMNASMN1; SMN2MAPK1ALDH1A1MAPT | |
| SCHEMBL17402455 | 0.87 | ALDH1A1 (0.55) | LMNASMN1; SMN2MAPK1ALDH1A1MAPT | |
| SCHEMBL18437982 | 0.87 | ALDH1A1 (0.55) | LMNASMN1; SMN2MAPK1ALDH1A1MAPT | |
| SCHEMBL18888908 | 0.85 | LMNA (0.45) | LMNASMN1; SMN2MAPK1ALDH1A1MAPT | |
| SCHEMBL17395772 | 0.85 | LMNA (0.47) | LMNASMN1; SMN2ALDH1A1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10675257-B2 | Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent | INFLECTIS BIOSCIENCE (FR) | 2020-06-09 | — | — | US | disclosed |
| US-20180221310-A1 | METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT | INFLECTIS BIOSCIENCE (FR) | 2018-08-09 | — | — | US | disclosed |
| US-20180221310-A1 | METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT | INFLECTIS BIOSCIENCE (FR) | 2018-08-09 | — | — | US | disclosed |
| WO-2017021216-A1 | METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT. | INFLECTIS BIOSCIENCE (FR) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221310-A1 | METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT | MGMT, GLI1, CA9 | LMNA 2920/4885SMN1; SMN2 154/4885MAPK1 2755/4885 |
| US-10675257-B2 | Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent | MGMT, GLI1, CA9 | LMNA 2920/4885SMN1; SMN2 154/4885MAPK1 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.